Viridian Therapeutics, Inc.\DE: Paradigm Biocapital Advisors LP amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Paradigm Biocapital Advisors LP amended its Schedule 13G filing on Viridian Therapeutics, disclosing a change in its passive stake in the company. The filing, submitted to the SEC under accession number 0001104659-26-128315, updates the investment firm's previously reported position in the biotech. The specific size and direction of the stake change were not detailed in the headline. The amendment matters because 13G updates signal shifts in institutional ownership that can influence Viridian's shareholder base and governance dynamics. Investors will watch for further 13G or 13D filings to confirm whether Paradigm is building or trimming its position.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Viridian Therapeutics, Inc., Paradigm Biocapital Advisors LP